Skin cancer

Global $5.848 Billion Radiotherapy Devices Market 2021: COVID-19 Growth and Change to 2030 - ResearchAndMarkets.com

Thursday, September 16, 2021 - 4:21pm

The "Radiotherapy Devices Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Radiotherapy Devices Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Artificial Intelligence (AI) is a leading trend in the radiotherapy devices market and is gaining significant popularity in the market.
  • The radiotherapy devices market covered in this report is segmented by product type into external beam radiation therapy devices; linear accelerator devices; proton therapy devices.
  • Therefore, the launch of advanced devices is likely to propel the revenues for the radiotherapy devices market in the near future.

American Skin Association Announces New Board Member Eugene A. Bauer, MD

Wednesday, September 15, 2021 - 4:36pm

NEW YORK, Sept. 15, 2021 /PRNewswire/ -- American Skin Association (ASA) today announced that Eugene Bauer, MD, will join its Board of Directors.

Key Points: 
  • NEW YORK, Sept. 15, 2021 /PRNewswire/ -- American Skin Association (ASA) today announced that Eugene Bauer, MD, will join its Board of Directors.
  • He is immediate past co-founder, Chief Medical Officer, and member of the Board of Directors of Dermira, Inc., a biotechnology company recently acquired by Eli Lilly and Company.
  • "We are proud to announce the addition of Dr. Eugene Bauer to ASA's Board of Directors.
  • Prior to that, he was co-founder and member of the Board of Directors at Connetics, a commercial dermatology company.

U.S. Dermatology Partners is pleased to welcome experienced Dermatology Physician Assistant, Katlyn McClure to their Shoal Creek, Missouri location

Wednesday, September 15, 2021 - 8:00am

LIBERTY, Mo., Sept. 15, 2021 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to welcome experienced Dermatology Physician Assistant Katlyn McClure to their Shoal Creek, Missouri location

Key Points: 
  • LIBERTY, Mo., Sept. 15, 2021 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to welcome experienced Dermatology Physician Assistant Katlyn McClure to their Shoal Creek, Missouri location
    Katlyn McClure graduated from the University of Arkansas in Fayetteville, with a Bachelor of Science Exercise Science degree in 2016.
  • Immediately following graduation, Katlyn continued her education at the University of Arkansas in their Medical Sciences Physician Assistant program and graduated with honors in 2018.
  • From the start of her academic career, Katlyn found a passion for dermatology and valued the challenges continually presented in this field.
  • U.S. Dermatology Partners Chief Executive Officer Paul Singh said, "We are happy to welcome Ms. McClure to U.S. Dermatology Partners.

How to Remove Unwanted Hair Using a Cream, Lotion or Gel: American Academy of Dermatology

Tuesday, September 14, 2021 - 7:30pm

According to board-certified dermatologists from the American Academy of Dermatology, people can dissolve unwanted hair using products called depilatories.

Key Points: 
  • According to board-certified dermatologists from the American Academy of Dermatology, people can dissolve unwanted hair using products called depilatories.
  • To test a hair-removal cream, lotion or gel, Dr. Mabry recommends the following tips:
    Apply a quarter-sized amount to an area on which you want to remove hair.
  • To use a hair-removal cream, lotion or gel, Dr. Mabry shares these tips:
    Apply a thick, even layer over the hair you want to remove.
  • These tips are demonstrated in How to Remove Unwanted Hair Using a Cream, Lotion or Gel , a video posted to the AAD website and YouTube channel .

OncoBeta initiates international EPIC-Skin study with Rhenium-SCT® for the treatment of Skin Cancer

Thursday, September 9, 2021 - 5:21pm

The EPIC Skin study (Efficacy of Personalised Irradiation with Rhenium-SCT- for the treatment of non-melanoma skin cancer) is based on the proven effect of the -emitter rhenium-188 in the treatment of basal cell (BCC) and squamous cell carcinomas (SCC)1,2.

Key Points: 
  • The EPIC Skin study (Efficacy of Personalised Irradiation with Rhenium-SCT- for the treatment of non-melanoma skin cancer) is based on the proven effect of the -emitter rhenium-188 in the treatment of basal cell (BCC) and squamous cell carcinomas (SCC)1,2.
  • OncoBeta has contracted the Australian based Contract Research Organization (CRO) Molecule2Market (M2M) for this significant international, multicentre clinical study ( www.molecule2.com.au ).
  • The Rhenium-SCT utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers).
  • Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT (Skin Cancer Therapy), targeting non-melanoma skin cancers.

Naomi Osaka's KINLÒ Launches Functional Skincare Formulated for People of Color

Tuesday, September 7, 2021 - 2:26pm

LOS ANGELES, Sept. 7, 2021 /PRNewswire/ -- Four-time Grand Slam tennis champion and activist Naomi Osaka launches KINL, a functional skincare brand that is formulated specifically for people with melanated skin.

Key Points: 
  • LOS ANGELES, Sept. 7, 2021 /PRNewswire/ -- Four-time Grand Slam tennis champion and activist Naomi Osaka launches KINL, a functional skincare brand that is formulated specifically for people with melanated skin.
  • These points have all led me to create KINL, a mission-first brand," says founder and CEO Naomi Osaka.
  • Made with clean formulations, KINL offers an assortment of active and recovery skincare products built to protect and rejuvenate melanated skin tones.
  • KINL is a functional skincare brand founded by Naomi Osaka in partnership with A-Frame brands.

Wave Life Sciences to Highlight RNA Editing Modality and PRISM Platform Advancements During Upcoming Scientific Conferences

Tuesday, September 7, 2021 - 1:30pm

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced it will highlight its ADAR-mediated RNA editing (ADAR editing) capability and PRISMTM platform advancements at upcoming scientific conferences.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced it will highlight its ADAR-mediated RNA editing (ADAR editing) capability and PRISMTM platform advancements at upcoming scientific conferences.
  • At OTS, we will also highlight our discovery-stage alpha-1 antitrypsin deficiency program, as well as our leading ADAR editing modality.
  • Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases.
  • Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Crescita Acquires Minority Interest in The Best You®

Tuesday, September 7, 2021 - 12:30pm

Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (Crescita or the Company), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced that it has completed the acquisition of a minority interest in Akyucorp Ltd. d/b/a The Best You, a privately-held network of six medical aesthetic clinics in the province of Ontario (The Best You).

Key Points: 
  • Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (Crescita or the Company), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced that it has completed the acquisition of a minority interest in Akyucorp Ltd. d/b/a The Best You, a privately-held network of six medical aesthetic clinics in the province of Ontario (The Best You).
  • In consideration for the minority interest investment, Crescita will issue 470,128, or 2.2% of its common shares (the Common Shares), at a price of $0.70 per Common Share.
  • The Convertible Note will bear interest at variable rates based on the annual volume of purchases of Crescita products and is convertible at Crescitas option into an additional equity interest in The Best You.
  • Dr. Deniz Akyurekli, MD, Founder and Chief Medical Officer of The Best You, said, At the Best You, we help customers look and feel their best to enhance their overall well-being and quality of life.

Move for Melanoma Teams Up with Vancouver Canucks' JT Miller to Raise $75,000 to Help Canadian Skin Cancer Patients Reach Treatment

Tuesday, September 7, 2021 - 9:30am

MOVE FOR MELANOMA challenges individuals and teams across Canada to participate in the activity challenge of their choice (ex.

Key Points: 
  • MOVE FOR MELANOMA challenges individuals and teams across Canada to participate in the activity challenge of their choice (ex.
  • while raising funds for Canadians touched by melanoma, non-melanoma skin cancers, and ocular melanoma.
  • MOVE FOR MELANOMA is an annual event hosted by Save Your Skin Foundation, the only organization in Canada that supports skin cancer patients financially when they need it most.
  • "We want to help fundraise to make sure patients can reach the treatment they need, so other families don't have to go through what we went through."

Genentech to Present Data From Industry-Leading Portfolio at ESMO 2021 Showing Significant Progress in Early Stage and Uncommon Cancers

Tuesday, September 7, 2021 - 6:00am

Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors.

Key Points: 
  • Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors.
  • Tecentriq is a prescription medicine used to treat adults with:
    A type of bladder and urinary tract cancer called urothelial carcinoma.
  • Continued approval for this use may depend on the results of an ongoing study to confirm benefit.
  • Patients should call or see their healthcare provider right away if they get any symptoms of the following problems or these symptoms get worse.